Alan Raffensperger appointed Chief Operating Officer
(Thomson Reuters ONE) -
Alan Raffensperger has been appointed Chief Operating Officer (COO) of Sobi with
responsibility for Sales & Marketing, Supply Chain, Procurement and IT. His most
recent position was CEO of Benechill Inc., an American medical device company
within the hypothermia therapeutic field. During the years 2005 to 2010 he was
employed by the American company Amgen and served as Executive Director, Head of
Nephrology 2008-2010 based at the international headquarters in Switzerland, and
General Manager of the Nordic and Baltic region 2005-2008, based in Sweden.
Prior to that he was Sales and Marketing Director at Roche Pharmaceuticals,
Sweden 1999-2004, Vice President, Global Marketing Diabetes Care at Roche
Diagnostics 1996-1998 based in Germany, and Business Director Europe, Diabetes
Care at Boeringher Mannheim 1994-1996, also based in Germany. He has also held
leading positions within Pharmacia in Sweden and USA.
Alan Raffensperger, born in 1960, holds a Bachelor of Science from University of
Maryland, Baltimore, USA. He will report to CEO Geoffrey McDonough and be a
member of the Executive Leadership Team. The appointment takes effect
immediately.
"We are delighted to welcome Alan to Sobi. The role of COO is part of the
changes we are making to increase the effectiveness of our commercial operation.
Alan brings an appropriate mix of operational and leadership experience in a
variety of roles which will help to foster the evolution of Sobi in the years
ahead," says Geoffrey McDonough, CEO of Sobi.
For further information, please contact:
Åsa Stenqvist, Head of Communications and Investor Relations
Tel.: +46 8 697 21 88
Swedish Orphan Biovitrum (Sobi)
Sobi is a leading integrated biopharmaceutical company dedicated to bringing
innovative therapies and services to improve the health of rare disease patients
and their families. The product portfolio comprises about 60 marketed products
as well as projects in the late clinical phase. Key therapeutic areas are
Inflammation and Genetics & Metabolism. In 2010 Sobi had revenues of SEK 1.9
billion and around 500 employees. The share (STO: SOBI) is listed on OMX NASDAQ
Stockholm. More information is available atwww.sobi.com.
The information above has been published pursuant to the Swedish Securities
Market Act and/or the Financial Instruments Trading Act. The information was
released for public distribution on 17 January 2012 at 11:15 a.m. CET.
Please follow the link below for a picture of Alan Raffensperger.
http://www.sobi.com/Investors--Media/Imagebank/Senior-Management/
Sobi Press Release on January 17th in pdf format:
http://hugin.info/134557/R/1578133/492245.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
[HUG#1578133]
Unternehmensinformation / Kurzprofil:
Datum: 17.01.2012 - 11:18 Uhr
Sprache: Deutsch
News-ID 104561
Anzahl Zeichen: 3572
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 235 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Alan Raffensperger appointed Chief Operating Officer"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
